Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Spyre Therapeutics Inc (SYRE)

Spyre Therapeutics Inc (SYRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

A Short Squeeze Could Send This Little-Known Biotech Stock Soaring

Valued at $2.6 billion, Spyre Therapeutics (SYRE) is a biotechnology company aiming to create inflammatory bowel disease products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection.  

I found today’s Chart of the Day by using Barchart’s powerful screening functions to sort for stocks with the highest technical buy signals; superior current momentum in both strength and direction; and a Trend Seeker “buy” signal. I then used Barchart’s Flipcharts feature to review the charts for consistent price appreciation. SYRE checks those boxes. Since the Trend Seeker signaled a new “Buy” on Oct. 8, the stock has...

Fundamentals

See More
  • Market Capitalization, $K 2,595,453
  • Shares Outstanding, K 77,592
  • Annual Sales, $ 0 K
  • Annual Income, $ -208,020 K
  • EBIT $ -214 M
  • EBITDA $ -225 M
  • 60-Month Beta 3.14
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 8.69

Options Overview Details

View History
  • Implied Volatility 81.99% (-8.01%)
  • Historical Volatility 64.17%
  • IV Percentile 4%
  • IV Rank 13.54%
  • IV High 222.63% on 09/16/25
  • IV Low 59.96% on 08/18/25
  • Expected Move (DTE 11) 7.99 (23.05%)
  • Put/Call Vol Ratio 10.34
  • Today's Volume 329
  • Volume Avg (30-Day) 194
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 4,983
  • Open Int (30-Day) 2,140
  • Expected Range 26.67 to 42.65

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.66
  • Number of Estimates 5
  • High Estimate -0.17
  • Low Estimate -1.31
  • Prior Year -0.81
  • Growth Rate Est. (year over year) +18.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
21.63 +60.45%
on 11/11/25
34.87 -0.47%
on 12/08/25
+12.19 (+54.11%)
since 11/07/25
3-Month
14.51 +139.26%
on 09/22/25
34.87 -0.47%
on 12/08/25
+18.08 (+108.69%)
since 09/08/25
52-Week
10.91 +218.10%
on 04/09/25
34.87 -0.47%
on 12/08/25
+7.63 (+28.16%)
since 12/06/24

Most Recent Stories

More News
A Short Squeeze Could Send This Little-Known Biotech Stock Soaring

Spyre Therapeutics (SYRE) has strong technical momentum and is trading at a new 52 week high. SYRE maintains a 100% “Buy” opinion from Barchart. Shares are up more than 50% in the past month. High...

SYRE : 34.79 (+4.01%)
Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies...

SYRE : 34.79 (+4.01%)
Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies...

SYRE : 34.79 (+4.01%)
Spyre Therapeutics: Q3 Earnings Snapshot

Spyre Therapeutics: Q3 Earnings Snapshot

SYRE : 34.79 (+4.01%)
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Reported positive interim Phase 1 results for SPY003, a next-generation anti-IL-23 antibody, demonstrating the molecule was well-tolerated and exhibited an ~85-day half-life supporting quarterly or twice...

SYRE : 34.79 (+4.01%)
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody

SPY003 was well tolerated and exhibited an ~85-day half-life, supporting potential quarterly or twice annual maintenance dosing SPY003 positive interim results unlock development of SPY130 (α4β7...

SYRE : 34.79 (+4.01%)
Spyre Therapeutics to Participate in Upcoming November Investor Conferences

WALTHAM, Mass., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine...

SYRE : 34.79 (+4.01%)
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025

WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine...

SYRE : 34.79 (+4.01%)
Spyre Therapeutics Announces Public Stock Offering

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Spyre Therapeutics...

SYRE : 34.79 (+4.01%)
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million

WALTHAM, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering,...

SYRE : 34.79 (+4.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Spyre Therapeutics is a biotechnology company which aims to create inflammatory bowel disease products by combining antibody engineering, rational therapeutic combinations and precision medicine approaches for patient selection. Spyre Therapeutics, formerly known as Aeglea BioTherapeutics Inc., is based...

See More

Key Turning Points

3rd Resistance Point 35.07
2nd Resistance Point 34.56
1st Resistance Point 34.01
Last Price 34.79
1st Support Level 32.95
2nd Support Level 32.44
3rd Support Level 31.89

See More

52-Week High 34.87
Last Price 34.79
Fibonacci 61.8% 25.72
Fibonacci 50% 22.89
Fibonacci 38.2% 20.06
52-Week Low 10.91

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar